Skip to main content
. 2020 Aug 12;123(9):1437–1444. doi: 10.1038/s41416-020-1024-2

Fig. 4. Dynamic detection of EGFR mutations in plasma using a dEGFR39 panel.

Fig. 4

EGFR frequency of activated mutations decreases initial reception of TKI treatment and subsequently increases (a, e); T790M mutation was not observed (c); emergence of resistant mutation was detected 2 months and 8 months prior to clinical PD, respectively (b, f), and the activated mutation was never cleared at the beginning of TKI treatment (d). The arrow refers to the result of significant changes in the patientʼs tissue samples by ARMS or imaging tests.